ARGX-213
Phase 1Biologic
ArgenxARGX-213 is one of 46 biologic programs targeting ESS. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
56 competitors in ESS
#DrugCompanyPhaseTrials
1Lexapro
AbbVieApproved
Proamatine
TakedaApproved
Quviviq
Idorsia Pharmaceuticals Ltd.Approved
Opdivo
Bristol-Myers SquibbPhase 2
Opdualag
Bristol-Myers SquibbPhase 2
Darzalex
Johnson & JohnsonPhase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Kyprolis
VVirionyx Corporation Limited
Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Mineral Trioxide Aggregate
JJordan University of Science and Technology
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARGX-213. EMBL-EBI & Wellcome Sanger Institute.
- [4]